Navigation Links
Estrogen alone is effective for reducing breast cancer risk
Date:12/9/2010

SAN ANTONIO While endogenous estrogen (i.e., estrogen produced by ovaries and by other tissues) does have a well-known carcinogenic impact, hormone replacement therapy (HRT) utilizing estrogen alone (the exogenous estrogen) provides a protective effect in reducing breast cancer risk, according to study results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

"Our analysis suggests that, contrary to previous thinking, there is substantial value in bringing HRT with estrogen alone to the guidelines. The data show that for selected women it is not only safe, but potentially beneficial for breast cancer, as well as for many other aspects of women's health," said lead researcher Joseph Ragaz, M.D., medical oncologist and clinical professor in the faculty of medicine, School of Population and Public Health at The University of British Columbia, Vancouver, BC, Canada.

"These findings should intensify new research into its role as a protective agent against breast cancer," he added.

Ragaz and colleagues reviewed and reanalyzed data from the Women's Health Initiative (WHI) hormone replacement therapy trials. WHI is a national health study that focuses on strategies for preventing heart disease, breast and colorectal cancer, and fracture in postmenopausal women. The WHI was launched in 1991 and includes more than 161,000 U.S. women aged 50 to 79 years.

"Over the last 30 years HRT has been used almost indiscriminately by women expecting the benefit of reducing cardiac risks, while providing a protective effect against bone fracture, and improving overall quality of life," said Ragaz. "The WHI results as originally interpreted led to a major pendulum swing against HRT."

The WHI HRT trial consisted of two cohorts of women; the estrogen-alone group of women without a uterus and the estrogen-plus-progestin group of women with a uterus.

Ragaz and colleagues reanalyzed the WHI studies in more detail and found that subsets of women with no strong family history of breast cancer who received estrogen alone had a significantly reduced breast cancer incidence. In addition, the 75 percent of women without benign disease prior to the trial enrollment also had a reduced breast cancer risk.

"Reduction of rates of breast cancer in the majority of women who are candidates for estrogen-based HRT is a new finding because estrogen was always linked with a higher incidence of breast cancer," Ragaz said, "yet estrogen administered exogenously is actually protective for most women."

Based on the results of this current analysis, Ragaz suggested that "while the use of HRT with estrogen alone may reduce the risk of breast cancer and may also be appropriate to manage menopausal symptoms, further research is warranted to elaborate on the optimum treatment regimen, to refine the selection of ideal candidates for estrogen therapy, and to understand the estrogen mechanisms that support the prevention of human breast cancer."

"The recommendations based on prior analyses of the results of the WHI HRT studies was not to use HRT, but we are optimistic this will change," he said. "Our conclusion, based on the data presented, should enhance considerations for an early approval of HRT based on estrogen-alone for the majority of selected women suffering with menopausal symptoms and galvanize new research on HRT to define the optimum regimens for individual women."


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. New estrogen receptor found to be key player in tamoxifen resistance
2. Estrogen-dependent switch tempers killing activity of immune cells
3. Supplement blocks the initiation of breast cell mutations by estrogens
4. Gallbladder cancer may be linked to estrogens, says UH team
5. UC research: Rabbits food brings luck in decreasing estrogen levels in wastewater
6. PET scans reveal estrogen-producing hotspots in human brain
7. Infant estrogen levels tracked through diaper research
8. New report: Dont blame the pill for estrogen in drinking water
9. Caltech-led researchers find negative cues from appearance alone matter for real elections
10. For cancer cells, genetics alone is poor indicator for drug response
11. Enzyme doesnt act alone in atrial fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... N.C. , Dec. 6, 2016 Valencell ... announced today it has seen a third consecutive year ... biometric sensor technology in 2016 with a 360 percent ... last year. This increase was driven by sales of ... as robust interest in its technology for hearables for ...
(Date:12/5/2016)...  The Office of Justice Programs, National Institute ... Enhance or Replace Medico Legal Autopsies?" on NIJ.gov.  ... replacing forensic autopsies with postmortem X-ray computed tomography, ... response to recommendations made by The National Academy ... as a potential component of medicolegal death investigations. ...
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe ... announced BioLock , an electrocardiogram (ECG) biosensor ... monitoring, a key IoT asset. The smart system ... a vehicle,s steering wheel and mobile devices to ... touch. As vehicle technology advances, so ...
Breaking Biology News(10 mins):
(Date:1/16/2017)...  Eurofins Genomics today announced the expansion of its ... receive their primers in a shorter turnaround time, without ... with other providers. Express oligos are available for anyone ... no additional fee. Researchers use the oligos ... sequencing, genotyping, site-directed mutagenesis, and cloning. Often, they are ...
(Date:1/13/2017)... Research and Markets has announced the addition of the "Global ... ... CAGR of 16.83% during the period 2017-2021. The report ... market for 2017-2021. To calculate the market size, the report considers the ... also includes a a discussion of the key vendors operating in this ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... SUCCESS , VTI, Vertebral Technologies, Inc., announces the successful outcome of the ... Since September 2016, VTI (Vertebral Technologies, Inc.) has partnered with Mexico-based medical ...
(Date:1/12/2017)... (PRWEB) , ... January 12, 2017 , ... ... to targeted treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a few months ... a new drug combination that has stabilized Rosendahl’s disease and increased both the ...
Breaking Biology Technology: